doi: 10.3389/fmed.2025.1643415 Received 08 June 2025 Accepted 25 September 2025 Published 14 October 2025 Volume 12 - 2025 Edited by Xin Hu, National Center for Child Health and Development (NCCHD), Japan Reviewed by Hua Miao, Northwest University, China Allan Kardec Barros, Universidade Federal do Maranho, Brazil ChandraShekar Annamalai, MVM College of Allied Health Sciences, India Updates Copyright 2025 Wang, Yuan, Wu and Ou
also reports having received royalty payments for inventions or discoveries related to cardiovascular diagnostics or therapeutics from Cleveland Heart Lab, a fully owned subsidiary of Quest Diagnostics and Procter & Gamble
The large TRAVERSE trial (2023, 5,204 men) found no increased cardiovascular risk at physiological doses
Addressing mitochondrial dysfunction, redox imbalance, and impaired energy metabolism could lead to more effective treatments